Literature DB >> 24203841

Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands.

Angel M R Schols1, Floris H B M Schreuder, Elisabeth P M van Raak, Tobien H C M L Schreuder, Fergus A Rooyer, Robert J van Oostenbrugge, Julie Staals.   

Abstract

BACKGROUND AND
PURPOSE: The aim of this study was to estimate the annual adult incidence and risk of intracerebral hemorrhage (ICH) and oral anticoagulant-associated ICH (OAC-ICH) in the Netherlands.
METHODS: We retrospectively selected all consecutive adult patients with a nontraumatic ICH seen in 1 of 3 hospitals in the region South-Limburg, the Netherlands, from 2007 to 2009. Crude incidences were age-adjusted to Dutch and European population.
RESULTS: We identified 652 ICH cases, of which 168 (25.8%) were OAC associated. The adult Dutch age-adjusted annual incidence of ICH and OAC-ICH was 34.8 (95% confidence interval, 32.0-37.8) and 8.7 (95% confidence interval, 7.3-10.3) per 100 000 person-years, respectively. The absolute risk of OAC-ICH was estimated at 0.46% per patient-year of OAC treatment.
CONCLUSIONS: The annual incidences of ICH and OAC-ICH are relatively high in the Netherlands when compared with international literature.

Entities:  

Keywords:  anticoagulants; cerebral hemorrhage; epidemiology; incidence

Mesh:

Substances:

Year:  2013        PMID: 24203841     DOI: 10.1161/STROKEAHA.113.003003

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

1.  Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: A European Stroke Organisation guideline.

Authors:  Catharina Jm Klijn; Maurizio Paciaroni; Eivind Berge; Eleni Korompoki; Janika Kõrv; Avtar Lal; Jukka Putaala; David J Werring
Journal:  Eur Stroke J       Date:  2019-04-09

2.  Safety of catheter ablation for atrial fibrillation in patients with intracranial hemorrhage.

Authors:  H Lin; S-N Li; R Bai; S-N Wen; N Liu; D-Y Long; R-H Yu; R-B Tang; C-H Sang; X Du; J-Z Dong; C-S Ma
Journal:  Herz       Date:  2017-03-17       Impact factor: 1.443

3.  Journal Club: Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage.

Authors:  Andreas Charidimou; Andrea Morotti; Raffaella Valenti; Anne-Katrin Giese; Gregoire Boulouis; Marco Pasi; Duangnapa Roongpiboonsopit; Arne Lauer; Li Xiong; Thijs Wijnzen Van Harten; Hasan Karadeli; Panagiotis Fotiadis; Michael James Jessel; Anand Viswanathan
Journal:  Neurology       Date:  2016-05-17       Impact factor: 9.910

4.  Early seizures after intracerebral hemorrhage predict drug-resistant epilepsy.

Authors:  Bianca T A de Greef; Floris H B M Schreuder; Mariëlle C G Vlooswijk; A H C M L Schreuder; Fergus A Rooyer; Robert J van Oostenbrugge; Rob P W Rouhl
Journal:  J Neurol       Date:  2014-12-05       Impact factor: 4.849

5.  Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage.

Authors:  Adrian R Parry-Jones; Mario Di Napoli; Joshua N Goldstein; Floris H B M Schreuder; Sami Tetri; Turgut Tatlisumak; Bernard Yan; Koen M van Nieuwenhuizen; Nelly Dequatre-Ponchelle; Matthew Lee-Archer; Solveig Horstmann; Duncan Wilson; Fulvio Pomero; Luca Masotti; Christine Lerpiniere; Daniel Agustin Godoy; Abigail S Cohen; Rik Houben; Rustam Al-Shahi Salman; Paolo Pennati; Luigi Fenoglio; David Werring; Roland Veltkamp; Edith Wood; Helen M Dewey; Charlotte Cordonnier; Catharina J M Klijn; Fabrizio Meligeni; Stephen M Davis; Juha Huhtakangas; Julie Staals; Jonathan Rosand; Atte Meretoja
Journal:  Ann Neurol       Date:  2015-05-14       Impact factor: 10.422

6.  Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.

Authors:  Rahat Amadkhan Abdoellakhan; Ishita Parveen Miah; Nakisa Khorsand; Karina Meijer; Korné Jellema
Journal:  Neurocrit Care       Date:  2017-02       Impact factor: 3.210

7.  Reliability of the intracerebral hemorrhage score for predicting outcome in patients with intracerebral hemorrhage using oral anticoagulants.

Authors:  M O Fakiri; M Uyttenboogaart; R Houben; R J van Oostenbrugge; J Staals; G J Luijckx
Journal:  Eur J Neurol       Date:  2020-06-16       Impact factor: 6.089

8.  STudy of Antithrombotic Treatment after IntraCerebral Haemorrhage: Protocol for a randomised controlled trial.

Authors:  Kristin Tveitan Larsen; Elisabeth Forfang; Johanna Pennlert; Eva-Lotta Glader; Christina Kruuse; Per Wester; Hege Ihle-Hansen; Maria Carlsson; Eivind Berge; Rustam Al-Shahi Salman; Torgeir Bruun Wyller; Ole Morten Rønning
Journal:  Eur Stroke J       Date:  2020-09-03

9.  Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.

Authors:  Koen M van Nieuwenhuizen; H Bart van der Worp; Ale Algra; L Jaap Kappelle; Gabriel J E Rinkel; Isabelle C van Gelder; Roger E G Schutgens; Catharina J M Klijn
Journal:  Trials       Date:  2015-09-04       Impact factor: 2.279

10.  Predicting Prognosis of Intracerebral Hemorrhage (ICH): Performance of ICH Score Is Not Improved by Adding Oral Anticoagulant Use.

Authors:  Rik Houben; Floris H B M Schreuder; Kim J Bekelaar; Danny Claessens; Robert J van Oostenbrugge; Julie Staals
Journal:  Front Neurol       Date:  2018-02-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.